Skip to main content
PREDILIFE logo

PREDILIFE — Investor Relations & Filings

Ticker · ALPRE ISIN · FR0010169920 LEI · 9695006IK5NBKHQU9116 PA Human health and social work activities
Open in API
Filings indexed 150 across all filing types
Latest filing 2022-01-19 Report Publication Anno…
Country FR France
Listing PA ALPRE

About PREDILIFE

https://www.predilife.com/en/

PREDILIFE specializes in predictive medicine, developing solutions to assess an individual's risk of developing major diseases. The company's approach integrates medical data, such as genetic testing and imaging, with artificial intelligence and mathematical models to create personalized risk profiles. Its primary offerings are predictive health check-ups, including a specialized test for assessing the 5-year risk of breast cancer (MammoRisk®) and a multi-condition check-up that evaluates the risk for several common cancers (lung, prostate, colorectal, melanoma) and cardiovascular disease. Based on these risk profiles, PREDILIFE provides personalized follow-up and preventive recommendations. The company offers its end-to-end solution, which includes remote consultations, to businesses, insurers, and healthcare professionals to facilitate wider access to preventive care.

Recent filings

Filing Released Lang Actions
BILAN SEMESTRIEL AU 31 DÉCEMBRE 2021 DU CONTRAT DE LIQUIDITÉ CONTRACTÉ AVEC TSAF - TRADITIONS SECURITIES AND FUTURES
Report Publication Announcement Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and is dated January 19, 2022. The subject is the "BILAN SEMESTRIEL AU 31 DÉCEMBRE 2021 DU CONTRAT DE LIQUIDITÉ CONTRACTÉ AVEC TSAF – TRADITIONS SECURITIES AND FUTURES" (Semi-annual statement as of December 31, 2021, for the liquidity contract with TSAF). This document details the activity (purchases and sales of shares) under a liquidity contract over the second half of 2021 and reports the resulting share and cash balances as of the period end date (31/12/2021). This type of periodic disclosure regarding market making or liquidity provision activities is a specific regulatory or contractual requirement, but it does not fit neatly into the major categories like 10-K (Annual Report), IR (Interim Report), or ER (Earnings Release). It is a specific financial/market operation update. Given the options, it is a specialized financial disclosure. Since it is a formal, periodic report on a specific financial arrangement (liquidity contract), and not a general announcement of a report's publication (RPA) or a general regulatory filing (RNS), it most closely aligns with a specialized financial update. However, none of the codes perfectly match 'Liquidity Contract Report'. Comparing the definitions, it is not an AGM, 10-K, AR, MANG, CT, CAP, DVA, DLST, DIRS, ER, SR, FS, CGR, IRAT, IR, IP, LTR, TAR, MRQ, MDA, NAV, DIV, PSI, DEF 14A, SHA, or POS. It is a report detailing financial activity. If we must choose the closest fit among the provided codes, a report detailing specific financial operations and balances, especially those related to market stability or financing structure, might fall under Capital/Financing Update (CAP) or be treated as a general Regulatory Filing (RNS) if no better fit exists. Since it is a detailed, periodic report on a specific financial mechanism (liquidity contract), and not a general earnings report, RNS is the most appropriate fallback for a specific, non-core financial disclosure not explicitly listed. The document is substantial (over 10,000 characters) and contains detailed transactional data, so it is the report itself, not just an announcement of one.
2022-01-19 French
PREDILIFE ANNONCE LE SUCCES DE SON AUGMENTATION DE CAPITAL POUR ACCELERER SON DEVELOPPEMENT ET SA CROISSANCE
Capital/Financing Update Classification · 1% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) dated December 22, 2021, and its main subject is the announcement of the success of a capital increase ("AUGMENTATION DE CAPITAL"). This type of announcement, detailing fundraising, issuance of new shares, and the resulting capital structure changes, directly corresponds to the definition of a Capital/Financing Update. The key elements supporting this classification are: 1. Title: "PREDILIFE ANNONCE LE SUCCES DE SON AUGMENTATION DE CAPITAL..." 2. Content: Details the gross amount raised (1.12 million euros), the number of new shares issued (168,168), the subscription price (6.70 euros), and the intended use of the funds. 3. This fits the definition for Capital/Financing Update (Code: CAP): "Updates on company fundraising, financing activities, or capital structure changes." It is not an Earnings Release (ER) as it focuses purely on financing, not operational results. It is not a 10-K or IR as it is a short press release about a specific event, not a comprehensive periodic report. It is not a Share Issue/Capital Change (SHA) because while it involves shares, the primary focus and format (a press release announcing the successful completion of the fundraising effort) aligns better with the broader 'CAP' category for financing activities.
2021-12-22 French
PARTENARIAT STRATEGIQUE AVEC EUROFINS POUR LA REALISATION DES TESTS GENETIQUES
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) dated December 16, 2021. It announces a strategic partnership between PREDILIFE and EUROFINS for genetic testing. This type of announcement, detailing a significant business development or agreement, does not fit the specific definitions for financial reports (10-K, IR, ER), shareholder actions (DIV, DVA), or management changes (MANG). Since it is a general business announcement that doesn't fit the highly specific categories like M&A (TAR) or Capital Change (CAP), the most appropriate fallback category is Regulatory Filings (RNS), which serves as a general category for miscellaneous regulatory or significant corporate announcements not covered elsewhere. The document length is short (2897 chars), but it is the primary announcement itself, not an announcement *of* another report, so RPA is less suitable than RNS for a general press release about a partnership.
2021-12-16 French
PREDILIFE SELECTIONNEE PAR L'UNION EUROPEENNE DANS LE CADRE DU PROGRAMME EUROPEAN INNOVATION COUNCIL ACCELERATOR
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) dated December 13, 2021. It announces that PREDILIFE has been selected by the European Union's European Innovation Council (EIC) Accelerator program. This is a general announcement regarding a significant business development (receiving EU selection/funding potential) rather than a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). Since it is a press release announcing a corporate event/achievement that doesn't fit the specific categories like M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS), the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory or significant corporate announcements not covered elsewhere.
2021-12-13 French
PREDILIFE LANCE UNE AUGMENTATION DE CAPITAL D'UN MONTANT MAXIMUM BRUT DE 2 MILLIONS D'EUROS (EN CAS D'EXERCICE DE LA CLAUSE D'EXTENSION ET DE L'OPTION DE SURALLOCATION) POUR ACCELERER SON DEVELOPPEMEN
Capital/Financing Update Classification · 1% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE" (Press Release) dated November 29, 2021. The core subject is the launch of a capital increase ("augmentation de capital") with a maximum gross amount of 2 million Euros, detailing the subscription price, priority period, and public offering timeline. This content directly relates to fundraising and capital structure changes. Based on the definitions, the most appropriate classification is 'Capital/Financing Update' (CAP). Although it is a press release, its specific content overrides the general 'RPA' or 'RNS' fallback, as 'CAP' is a more precise fit for a financing announcement.
2021-11-29 French
MAMMORISK INTÉGRALEMENT REMBOURSÉ POUR LES SALARIÉES D'ALLIANZ FRANCE
Environmental & Social Information Classification · 1% confidence The document is a press release dated November 25, 2021, announcing that PREDILIFE's MammoRisk device is fully reimbursed for Allianz France employees. This is an announcement regarding a business development, partnership, or specific corporate event that is not a standard periodic financial filing (like 10-K or IR) or a direct financial result announcement (ER). It details a specific corporate action/agreement. Since it doesn't fit perfectly into categories like M&A (TAR), Capital Change (CAP), or Dividend (DIV), and it is a general corporate announcement, the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory or significant corporate news releases that aren't covered by more specific codes.
2021-11-25 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.